AbbVie enters its July 31 second-quarter report as one of the most quietly compelling transformations in large-cap pharma. The company spent years defined by a single question: what happens when Humira loses patent protection? That answer is now visible in the quarterly filings. Skyrizi and Rinvoq are growing fast enough to make the Humira erosion almost irrelevant. The harder question is whether a $450-billion-plus market cap, built on drugs that are still mid-cycle, has already priced in a decade of outperformance.
This morning’s report lands alongside a $10.9 billion acquisition still pending close, a full-year earnings guidance reset driven by deal-related accounting, and a stock trading within shouting distance of its all-time high. Each of those facts pulls in a different direction. Sorting through them is the job of this issue.
The Market Context
The pharmaceutical sector has spent three years in a slow-motion reckoning with post-COVID volatility, patent cliffs, and policy uncertainty around drug pricing. AbbVie was supposed to be the cautionary tale. Humira, which generated roughly $20 billion in annual revenue at its peak, lost U.S. exclusivity in 2023 and immediately faced biosimilar competition that should have cratered the top line.
It didn’t crater the top line because Skyrizi and Rinvoq absorbed the shock. In Q1 2026, the two drugs together generated more than $6.6 billion in quarterly revenue while Humira contributed $688 million globally, down 38.6% year over year. The math has already inverted: the drugs that were supposed to replace Humira have surpassed what Humira was doing at its commercial peak, and both are still expanding into new indications.
That structural shift is what makes today’s report matter beyond the usual EPS-versus-consensus exercise. AbbVie is not defending a legacy position. It is running two growth franchises simultaneously while building a third leg through neuroscience.
The Research
Coming into the Q2 report, analysts expected approximately $16.7 billion in revenue with adjusted EPS in the range of $3.57 to $3.61. Those numbers already include a $291 million acquired in-process R&D and milestone charge related to a recent business development transaction, which reduces both GAAP and adjusted diluted EPS by $0.17 per share. Remove that one-time charge, and the underlying operating picture looks considerably cleaner than the headline EPS will suggest.
The immunology franchise is carrying the growth burden. In Q1 2026, Skyrizi posted $4.483 billion in quarterly revenue, up 30.9% year over year, while Rinvoq contributed $2.119 billion, up 23.3%. Wall Street consensus for Q2 placed Skyrizi at approximately $5.52 billion and Rinvoq at $2.49 billion. Those are not trivial figures. Combined, they would represent roughly half of the entire quarterly revenue base.
Neuroscience has also become a genuine second pillar. In Q1, total neuroscience revenues reached $2.875 billion, up 26% year over year. Vraylar contributed $905 million, Botox Therapeutic crossed $1.009 billion in a single quarter for the first time ever, and migraine drugs Ubrelvy and Qulipta combined for $635 million. These numbers matter because neuroscience was an afterthought five years ago. Today it generates more revenue than most standalone specialty pharma companies.
AbbVie’s trailing four-quarter average earnings surprise stands at 2.72%, and the company has beaten revenue expectations in four consecutive quarters. The bar coming into today is not low, but the underlying commercial momentum supports clearing it again.
The Hidden Insight
The most underappreciated development at AbbVie is not the Skyrizi growth rate or even the neuroscience expansion. It is the $10.9 billion all-cash acquisition of Apogee Therapeutics, announced June 22, which adds a late-stage immunology pipeline in two of the highest-unmet-need categories in medicine: atopic dermatitis and severe asthma.
Apogee’s lead asset, zumilokibart (APG777), is a half-life extended monoclonal antibody targeting interleukin-13, currently in late-stage development for atopic dermatitis. A second candidate, APG273, is a combination of zumilokibart and APG333 targeting both IL-13 and thymic stromal lymphopoietin, being developed for asthma. These are not speculative molecules. They are clinical-stage assets with positive interim data that fill an indication gap Skyrizi and Rinvoq do not currently address.
Here is the second-order read most investors are skipping. Atopic dermatitis is already dominated by Dupixent, Sanofi and Regeneron’s blockbuster biologic, which generated more than $18 billion globally in 2025. A half-life extended entrant with similar mechanism and better dosing convenience is a credible commercial threat. AbbVie already knows the inflammatory disease payer landscape better than almost anyone. Zumilokibart would step into a market where AbbVie has existing relationships, established patient access infrastructure, and a sales force already calling on the same dermatologists.
The deal is expected to accrete to adjusted earnings beginning in 2032, which means investors are currently holding the liability without the payoff. That timeline matters because it suggests the market is not pricing in Apogee’s pipeline at all. The $10.9 billion is a cost today. The optionality sits in the mid-2030s revenue curve, invisible in every near-term financial model.
Investment Opportunities
AbbVie (NYSE: ABBV) sits near its all-time high with a 52-week range of $187.62 to $267.47. At roughly $257, the stock trades at approximately 18x forward adjusted earnings, a material discount to the S&P 500’s ~20x multiple, despite growing revenues at roughly 10% annually with significantly lower volatility.
The 2.7% to 2.8% dividend yield, supported by a $1.73 quarterly payout, adds a durable income component. The most recent quarterly hike raised the dividend from $1.64 to $1.73, a 5.5% increase, continuing a run of consistent payout growth. For an institutional allocation, that combination of below-market volatility, 10% revenue growth, and a growing dividend in a rate-uncertain environment is unusually difficult to replicate.
The Apogee deal creates a longer-range option on two categories, atopic dermatitis and severe asthma, where the commercial logic is strong and the clinical differentiation is meaningful. Even under conservative assumptions, the pipeline adds value that no current analyst target fully captures.
Risks and Counterarguments
Three risks deserve specific attention. First, the Humira erosion is not finished. The drug generated $688 million in Q1. The consensus estimate for Q2 is approximately $730 million, but that number will keep declining as biosimilar penetration deepens. The offset math depends on Skyrizi and Rinvoq sustaining above-20% growth rates into new indications. If either drug experiences faster-than-expected competitive pressure, the growth story gets complicated quickly.
Second, the Apogee acquisition places a premium on clinical execution. Zumilokibart is still in development. Phase 3 data will determine whether APG777 can achieve the label breadth and differentiated profile needed to compete against Dupixent at scale. The acquisition was priced at $135.11 per share. If the clinical data disappoints, that premium evaporates and $10.9 billion in deployed capital generates no return.
Third, the full-year adjusted EPS guidance, now set at $13.91 to $14.11, has already been revised down due to acquired in-process R&D and milestone expense recorded in connection with business development. Any further business development activity that triggers additional milestone payments could create additional noise that obscures the underlying operating trend. The market has been willing to look through these charges. That patience is not unlimited.
Research Conclusion
AbbVie’s Q2 report is not a binary event. The company’s commercial trajectory has been consistent enough across the past several quarters that the specific earnings print matters less than what management says about Skyrizi’s progression into inflammatory bowel disease, Rinvoq’s alopecia areata filing status, and the initial integration timeline for the Apogee assets.
The structural argument for the stock is intact: two growing blockbusters replacing a declining one, a neuroscience business expanding into new disease areas, and a pipeline acquisition that adds a decade of optionality at a valuation the current stock price does not reflect. The near-term noise around deal charges and Humira declines is real but manageable.
What investors should monitor in the weeks ahead: Skyrizi’s Q2 revenue versus the $5.52 billion estimate, any updated commentary on Rinvoq’s alopecia areata FDA submission, the Apogee deal close timeline, and whether management maintains or raises the full-year revenue guidance of approximately 10% growth. If all four items check out, the current price near the all-time high looks less like a ceiling and more like a launching point for the next leg of this transformation.
